CTSO - Cytosorbents Corporation
| Previous Close | 11.0000 |
| Open | 10.9100 |
| Bid | 10.7500 x 1400 |
| Ask | 10.7800 x 2900 |
| Day's Range | 10.7500 - 11.0900 |
| 52 Week Range | 5.8000 - 14.9500 |
| Volume | 76,498 |
| Avg. Volume | 231,046 |
| Market Cap | 339.132M |
| Beta (3Y Monthly) | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4920 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.13 |
- PR Newswire•4 hours ago
CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences
MONMOUTH JUNCTION, N.J. , Oct. 18, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly ...
- GlobeNewswire•3 days ago
Detailed Research: Economic Perspectives on LifePoint Health, Carter's, Lincoln Electric, Cytosorbents, ServiceNow, and Chimera Investment — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•15 days ago
CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference
MONMOUTH JUNCTION, N.J. , Oct. 3, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•28 days ago
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
MONMOUTH JUNCTION, N.J. , Sept. 20, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- Simply Wall St.•last month
Do You Know Who Else Invests In Cytosorbents Corporation (NASDAQ:CTSO)?
Every investor in Cytosorbents Corporation (NASDAQ:CTSO) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...
- PR Newswire•last month
World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research
MONMOUTH JUNCTION, N.J., Sept. 13, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO) a critical care immunotherapy leader using its CytoSorb® blood purification technology to help patients survive sepsis and other life-threatening inflammatory conditions, commemorates World Sepsis Day 2018 today as a sponsor of the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research. What is sepsis? Watch this short video!
- Zacks Small Cap Research•last month
CTSO: FDA Approves REFRESH-2 Protocol Amendment
By Brian Marckx, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT FDA Approves REFRESH II Protocol Amendment This morning (9/4/2018) CytoSorbents (NASDAQ:CTSO) announced that FDA approved the protocol ...
- PR Newswire•last month
CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA
MONMOUTH JUNCTION, N.J. , Sept. 4, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader using its CytoSorb ® blood purification technology to treat deadly ...
- InvestorPlace•2 months ago
Cytosorbents Stock Could Score Big With Its Blood-Filtering Technology
Cytosorbents (NASDAQ:CTSO) is something of a hit in Europe but is virtually unknown in the U.S. Its blood-filtering technology, based on porous polymer beads that actively remove specific toxins from blood and other bodily fluids, is being built into a host of filtering products with names like CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, and DrugSorb.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CTSO earnings conference call or presentation 2-Aug-18 8:45pm GMT
Q2 2018 Cytosorbents Corp Earnings Call
- PR Newswire•2 months ago
CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter
MONMOUTH JUNCTION, N.J. , Aug. 21, 2018 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader specializing in blood purification, announced today that the National ...
- Zacks Small Cap Research•2 months ago
CTSO: Q2 Product Sales Beat Big. New Catalysts Come Online. Moving PT to $15/share
Q2 2018 Update: Product Sales Beat Big. Relative to the financials, it was a very strong quarter for product sales which set a new record high, jumping 18% from Q1 and almost 73% yoy. Product sales were also well ahead of our estimate and given the steeper than anticipated growth rate and new catalysts coming online, we have again made upward revisions to our forecasts.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties — Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cytosorbents ...
- Associated Press•2 months ago
CytoSorbents: 2Q Earnings Snapshot
The Monmouth Junction, New Jersey-based company said it had a loss of 19 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•3 months ago
CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
Quarterly CytoSorb Sales Reach $5.2 Million , With Trailing 12-month CytoSorb Sales of $17.4 Million MONMOUTH JUNCTION, N.J. , Aug. 2, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical ...
- ACCESSWIRE•3 months ago
CytoSorbents Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / CytoSorbents Corporation (NASDAQ: CTSO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:45 PM Eastern ...
- PR Newswire•3 months ago
CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide
MONMOUTH JUNCTION, N.J., July 31, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has expanded the distribution of CytoSorb® to a total of 53 countries worldwide. The Company also announced the change of the company's distributor in the United Kingdom to Chalice Medical Ltd., with a focus on England and Ireland. Dr. Christian Steiner, Senior Vice President of Sales and Marketing of CytoSorbents Corporation stated, "There is continued strong interest among clinicians and researchers from many countries around the world who have heard or learned about our CytoSorb therapy from international congresses and colleagues. They are hearing the positive experiences and are seeing the clinical data on how CytoSorb is helping to control deadly inflammation in critically-ill and cardiac surgery patients.
- PR Newswire•3 months ago
CytoSorbents to Report Q2 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , July 26, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly ...
- PR Newswire•3 months ago
Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society
PerLife™ Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid Organs for Transplantation MIRANDOLA, Italy and MONMOUTH JUNCTION, ...
- PR Newswire•4 months ago
CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes
The Russell 2000 Index is one of the most widely quoted benchmarks for small capitalization stocks in the U.S., representing approximately 2,000 small cap companies with a median market capitalization of $933 million, as of May 31, 2018. The Russell 2000 Index is a subset of the broader Russell 3000 Index that benchmarks the entire U.S. stock market.
- PR Newswire•4 months ago
CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility
MONMOUTH JUNCTION, N.J., June 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced receipt of regulatory approval to begin production of CytoSorb in its new manufacturing facility in Monmouth Junction, New Jersey, under the Company's ISO 13485:2003 certificate.
- PR Newswire•4 months ago
CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference
MONMOUTH JUNCTION, N.J. , June 4, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•5 months ago
CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference
MONMOUTH JUNCTION, N.J. , May 21, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•5 months ago
CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
Broadened indications expand the role of CytoSorb in treating liver disease and trauma MONMOUTH JUNCTION, N.J. , May 14, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy ...
- Zacks Small Cap Research•5 months ago
CTSO: Q1 2018 Update: Product Sales New Record. REFRESH 2 Enrollment Should Pick Up Steam. REMOVE Already Ramping
Product sales, while a hair below our estimate, continue to climb with Q1 marking the 11th consecutive quarter of setting a new high. Product sales growth is broad based – with both direct (i.e. CTSO is guiding for product sales to increase sequentially (i.e.
